세계의 PET용 방사성 트레이서 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2030년)

The global demand for PET Radiotracer Market is presumed to reach the market size of nearly USD 6.4 BN by 2030 from USD 3.17 BN in 2022 with a CAGR of 9.2% under the study period 2023 - 2030.

A PET radiotracer, also known as a PET radiopharmaceutical or PET tracer, is a radioactive compound used in Positron Emission Tomography (PET) imaging.It is a nuclear imaging technique that provides detailed images of the physiological and biochemical processes in the body.

MARKET DYNAMICS:

The increasing prevalence of cancer worldwide fuels the demand for PET imaging with radiotracers, which assist in cancer diagnosis and treatment evaluation. Advancements in molecular imaging and the development of new radiotracers expand the capabilities of PET imaging, making it applicable to various medical fields and physiological processes. The emphasis on early disease detection and personalized medicine further drives the demand for PET radiotracers. Research and development efforts in nuclear medicine result in the discovery of novel radiotracers, enhancing the availability and application of PET imaging. Increased funding, investments, and government support boost the commercialization and adoption of PET radiotracers. The growing ageing population contributes to the demand for PET imaging in age-related diseases, such as cancer and neurodegenerative disorders. PET radiotracers are also essential in drug development and clinical trials, assessing drug efficacy and target engagement. Favourable reimbursement policies and the integration of PET with other imaging modalities further support the growth of the PET radiotracer market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pet radiotracer. The growth and trends of pet radiotracer industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pet radiotracer market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Radiotracer Type

• F-18 (FDG18)
• Ga 68 (FAPI)
• Others

By Application

• Cancer
• Heart Disease
• Gastrointestinal
• Endocrine
• Neurological Disorders
• Others

By End-User

• Hospitals
• Diagnostic Centers
• Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the PET Radiotracer market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the PET Radiotracer market include ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.), Blue Earth Diagnostics, Cardinal Health., Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions, Jubilant Pharma Limited, Lantheus Holdings Inc., Siemens Healthineers AG, Yantai Dungcheng Pharmaceutical Group Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PET RADIOTRACER - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Radiotracer Type
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By End-user
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY RADIOTRACER TYPE

• 5.1 Overview by Radiotracer Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Radiotracer Type
• 5.4 F-18 (FDG18) Historic and Forecast Sales by Regions
• 5.5 Ga 68 (FAPI) Historic and Forecast Sales by Regions
• 5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY APPLICATION

• 6.1 Overview by Application
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Application
• 6.4 Cancer Historic and Forecast Sales by Regions
• 6.5 Heart Disease Historic and Forecast Sales by Regions
• 6.6 Gastrointestinal Historic and Forecast Sales by Regions
• 6.7 Endocrine Historic and Forecast Sales by Regions
• 6.8 Neurological Disorders Historic and Forecast Sales by Regions
• 6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY END-USER

• 7.1 Overview by End-user
• 7.2 Historical and Forecast Data
• 7.3 Analysis by End-user
• 7.4 Hospitals Historic and Forecast Sales by Regions
• 7.5 Diagnostic Centers Historic and Forecast Sales by Regions
• 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL PET RADIOTRACER MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE PET RADIOTRACER COMPANIES

• 9.1. Pet Radiotracer Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF PET RADIOTRACER INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.)
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Blue Earth Diagnostics
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Cardinal Health.
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Eli Lilly and Company
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. GE Healthcare
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. IBA Radiopharma Solutions
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. Jubilant Pharma Limited
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Lantheus Holdings Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Siemens Healthineers AG
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Yantai Dungcheng Pharmaceutical Group Co. Ltd.
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies